Clinical trial
Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia
NCT04095936 · Kyowa Kirin Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT04095936 |
|---|---|
| Title | Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia |
| Official title | A Phase 2/3 Study of AMG531 Combined With Ciclosporin A in Patients With Aplastic Anemia Previously Untreated With Immunosuppressive Therapy |
| Lead sponsor | Kyowa Kirin Co., Ltd., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Aplastic Anemia |
| Intervention type | Drug |
| Interventions | Romiplostim |
| Enrollment | 24 |
| Start date | Dec 3, 2019 |
| Primary completion | Oct 7, 2021 |
| Completion | Oct 29, 2021 |
| First posted | Sep 19, 2019 |
| Last update posted | May 26, 2022 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: